Cyclopharm Receives $3.1M R&D Tax Incentive for FY2020
Filed with ASX · · 1 page · English
Story so far
Earlier from Cyclopharm
- Cyclopharm Successfully Completes A$30 Million Placement
- SNMMI Requests USFDA to Expedite Approval For Technegas
- USFDA Approval Progress for Technegas and Business Update
- Cyclopharm Investor Presentation
- Technegas USA Trial Successfully Meets Primary Endpoint
Later from Cyclopharm
- Confirmation of Technegas USFDA Timetable
- S&P DJI Announces March 2021 Quarterly Rebalance
- Chairmans Address to Shareholders
- CYC 2021 AGM Presentation
- Managing Directors Address to Shareholders
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm